Granett, J.R.

patient trial tranilast group placebo restenosi study lotrafiban treatment disease point robert placebo group circulation end point angiographic swets subs service table aspirin david death /iiia event follow-up vessel mortality cerebrovascular disease month hazard randomized university figure heart platelet result lotrafiban group stroke frequency cerebrovascular angiographic restenosis william laboratory glycoprotein lesion jeffrey infarction revascularization reduction target hospital michael stenosi creatinine treatment groups efficacy 3 months 162 mg /d martin efficacy end point investigator ratio difference angioplasty pierre ischemic creatinine clearance service antagonist stent assoc value population safety monitoring board 325 mg /d downloaded angiography february stephen 50 mg bid topol